🇺🇸 FDA
Patent

US 10358433

Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity

granted A61KA61K31/444A61K31/4709

Quick answer

US patent 10358433 (Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity) held by Theravance Respiratory Company, LLC expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Respiratory Company, LLC
Grant date
Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61K, A61K31/444, A61K31/4709, A61K31/56, A61K45/06